Anti-leucine-rich glioma-inactivated 1 encephalitis revealed by a manic episode: insights from frontal lobe dysfunction in neuropsychiatry through neuropsychology and metabolic imaging. A case report.

FDG-PET anti-LGI1 encephalitis autoimmune manic syndrome behavior limbic encephalitis

Journal

Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006

Informations de publication

Date de publication:
2023
Historique:
received: 17 02 2023
accepted: 02 05 2023
medline: 5 6 2023
pubmed: 5 6 2023
entrez: 5 6 2023
Statut: epublish

Résumé

Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis is a limbic encephalitis that rarely presents as an isolated psychiatric syndrome. A 70-year-old patient first presented with behavioral disorder including hyperactivity, euphoria, with disinhibition and accelerated speech associated with severe insomnia and cognitive disorder. A manic episode was diagnosed and he received various psychotropic medications with no improvement. Invesitgations were negative (MRI showed T2 aspecific hyperintensities with no hyperintensities in limbic regions and EEG was normal). He was transferred to a nursing home, with a diagnosis of neurodegenerative condition. Later, he was referred to our unit for further investigations. A cerebral 18F-FDG-PET revealed an association of frontal hypometabolism and temporal and striatum hypermetabolism and CSF analysis revealed slightly increased white blood cell counts. Plasmatic anti-LGI1 antibodies were detected. The patient was treated with intra-venous immunoglobulin (IvIg) but showed no improvement. Second-line treatment (a combination of rituximab and cyclophosmphamide) was then administered for a year, leading to an improvement of neuropsychiatric symptoms and normalization of metabolic impairment on 18F-FDG-PET. In this report, we describe a novel case of a patient withanti-LGI1 encephalitis with a predominant long-term psychiatric presentation. An atypical presentation (such as atypical psychiatric symptoms, neurocognitive disorder, and hyponatremia) should prompt further investigations such as CSF analysis, considering that MRI and EEG may be normal. FDG-PET might be of interest but few data are available in the literature. Early treatment of anti-LGI1 encephalitis is crucial for overall prognosis and may delay the development of dementia in some cases.

Sections du résumé

Background UNASSIGNED
Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis is a limbic encephalitis that rarely presents as an isolated psychiatric syndrome.
Case presentation UNASSIGNED
A 70-year-old patient first presented with behavioral disorder including hyperactivity, euphoria, with disinhibition and accelerated speech associated with severe insomnia and cognitive disorder. A manic episode was diagnosed and he received various psychotropic medications with no improvement. Invesitgations were negative (MRI showed T2 aspecific hyperintensities with no hyperintensities in limbic regions and EEG was normal). He was transferred to a nursing home, with a diagnosis of neurodegenerative condition. Later, he was referred to our unit for further investigations. A cerebral 18F-FDG-PET revealed an association of frontal hypometabolism and temporal and striatum hypermetabolism and CSF analysis revealed slightly increased white blood cell counts. Plasmatic anti-LGI1 antibodies were detected. The patient was treated with intra-venous immunoglobulin (IvIg) but showed no improvement. Second-line treatment (a combination of rituximab and cyclophosmphamide) was then administered for a year, leading to an improvement of neuropsychiatric symptoms and normalization of metabolic impairment on 18F-FDG-PET.
Conclusion UNASSIGNED
In this report, we describe a novel case of a patient withanti-LGI1 encephalitis with a predominant long-term psychiatric presentation. An atypical presentation (such as atypical psychiatric symptoms, neurocognitive disorder, and hyponatremia) should prompt further investigations such as CSF analysis, considering that MRI and EEG may be normal. FDG-PET might be of interest but few data are available in the literature. Early treatment of anti-LGI1 encephalitis is crucial for overall prognosis and may delay the development of dementia in some cases.

Identifiants

pubmed: 37275973
doi: 10.3389/fpsyt.2023.1168302
pmc: PMC10233061
doi:

Types de publication

Case Reports

Langues

eng

Pagination

1168302

Informations de copyright

Copyright © 2023 Porpiglia, Guillaume, Bliaux, Psimaras, Decazes, Guillin, Rothärmel and Morin.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

BMC Neurol. 2014 Jun 20;14:136
pubmed: 24950993
Brain. 2015 Nov;138(Pt 11):3440-8
pubmed: 26373602
Rev Neurol (Paris). 2013 Feb;169(2):142-53
pubmed: 23099105
J Neuroimmunol. 2018 Apr 15;317:8-14
pubmed: 29501086
Neurology. 2016 Oct 4;87(14):1449-1456
pubmed: 27590293
Clin Nucl Med. 2013 May;38(5):392-4
pubmed: 23486322
Neurology. 2016 Aug 23;87(8):759-65
pubmed: 27466467
Australas Psychiatry. 2018 Dec;26(6):612-614
pubmed: 29756462
Neurology. 1988 Jun;38(6):900-3
pubmed: 3368071
Ann Neurol. 2008 Jul;64(1):97-108
pubmed: 18668637
Autoimmun Rev. 2016 Oct;15(10):970-4
pubmed: 27485013
J Neuroimmunol. 2013 Dec 15;265(1-2):75-81
pubmed: 24176648
Rev Neurol (Paris). 2018 Apr;174(4):228-236
pubmed: 29609960
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
Front Psychiatry. 2017 Feb 16;8:25
pubmed: 28261116
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
Brain Sci. 2020 Jun 16;10(6):
pubmed: 32560097
Acta Neurol Scand. 2005 May;111(5):338-43
pubmed: 15819715
J Affect Disord. 2006 Jul;93(1-3):105-15
pubmed: 16677713
Aust N Z J Psychiatry. 2018 Jul;52(7):714-715
pubmed: 29148280
Rinsho Shinkeigaku. 2013;53(9):706-11
pubmed: 24097318

Auteurs

Federica Porpiglia (F)

Department of Psychiatry, Rouvray Hospital, University of Rouen, Rouen, France.

Maxime Guillaume (M)

Department of Neurology and CNR-MAJ, CHU Rouen, Univ Rouen Normandie, UNIROUEN, Rouen, France.

Evangeline Bliaux (E)

Department of Neurology and CNR-MAJ, CHU Rouen, Univ Rouen Normandie, UNIROUEN, Rouen, France.

Dimitri Psimaras (D)

Department of Neurology 2-Mazarin AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

Pierre Decazes (P)

Department of Nuclear Medicine, Centre Henri-Becquerel, Rouen, France.

Olivier Guillin (O)

Department of Psychiatry, Rouvray Hospital, University of Rouen, Rouen, France.

Maud Rothärmel (M)

Department of Psychiatry, Rouvray Hospital, University of Rouen, Rouen, France.

Alexandre Morin (A)

Department of Psychiatry, Rouvray Hospital, University of Rouen, Rouen, France.
Department of Neurology and CNR-MAJ, CHU Rouen, Univ Rouen Normandie, UNIROUEN, Rouen, France.

Classifications MeSH